Grünenthal, Lead Discovery Center and Max Planck Society Enter Into a Research Collaboration on Charcot-Marie-Tooth 1A (CMT1A) - Seite 2
About Grünenthal
Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 bn company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 100 countries and approx. 5,200 employees are working for Grünenthal worldwide. In 2017, Grünenthal achieved revenues of approx. €1.3 bn.
More information: http://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Lesen Sie auch
Instagram: gruenenthal
About the Lead Discovery Center
The Lead Discovery Center was established in 2008 by Max-Planck Society as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.
The Lead Discovery Center sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Johnson & Johnson Innovation, Roche and Sotio as well as leading translational drug discovery centers around the globe. Further information at: http://www.lead-discovery.de
For further information, please contact:
Štěpán Kráčala, Head Global
Communications
Tel.: +49-241-569-1335
Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany
Public Relations LDC
Tel.: +49-231-9742-7000
pr@lead-discovery.de
Lead Discovery Center GmbH,
44227 Dortmund, Germany